Cognyte Software (CGNT) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cognyte Software in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CGNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CGNT, but not buy additional shares or sell existing shares.
View CGNT analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price targets for Cognyte Software's shares. Their CGNT share price forecasts range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests that the stock has a possible downside of 44.4%.
View analysts price targets for CGNT or view top-rated stocks among Wall Street analysts.

Cognyte Software's stock was trading at $3.11 at the beginning of the year. Since then, CGNT stock has increased by 73.6% and is now trading at $5.40.
View the best growth stocks for 2023 here.

Cognyte Software saw a decline in short interest in May. As of May 15th, there was short interest totaling 531,600 shares, a decline of 18.1% from the April 30th total of 648,900 shares. Based on an average trading volume of 272,700 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.8% of the shares of the stock are sold short.
View Cognyte Software's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 27th 2023.
View our CGNT earnings forecast.

Cognyte Software Ltd. (NASDAQ:CGNT) released its quarterly earnings results on Monday, December, 20th. The medical device company reported $0.21 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.11. The medical device company earned $118.70 million during the quarter, compared to the consensus estimate of $114.83 million. Cognyte Software had a negative net margin of 36.57% and a negative trailing twelve-month return on equity of 55.52%. The company's revenue was up 5.0% compared to the same quarter last year.

ETFs with the largest weight of Cognyte Software (NASDAQ:CGNT) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL).ETFMG Prime Cyber Security ETF (HACK).

Cognyte Software issued an update on its FY 2024 earnings guidance on Tuesday, April, 11th. The company provided earnings per share guidance of -$0.60--$0.60 for the period, compared to the consensus EPS estimate of -$0.69. The company issued revenue guidance of $294.00 million-$306.00 million, compared to the consensus revenue estimate of $287.53 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cognyte Software investors own include EndoChoice (GI), Novavax (NVAX), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Fc Global Realty (FCRE), Galectin Therapeutics (GALT), Immunomedics (IMMU), Iovance Biotherapeutics (IOVA), Neurocrine Biosciences (NBIX) and Nymox Pharmaceutical (NYMX).

Cognyte Software trades on the NASDAQ under the ticker symbol "CGNT."

Cognyte Software's stock is owned by many different institutional and retail investors. Top institutional shareholders include American Capital Management Inc. (7.14%), William Blair Investment Management LLC (4.33%), Ameriprise Financial Inc. (3.32%), Arrowstreet Capital Limited Partnership (1.36%), Dimensional Fund Advisors LP (1.01%) and BlackRock Inc. (0.91%).
View institutional ownership trends.

Shares of CGNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CGNT stock can currently be purchased for approximately $5.40.

Cognyte Software (NASDAQ:CGNT) has a market capitalization of $371.74 million and generates $312.06 million in revenue each year. The medical device company earns $-114,130,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

The company employs 1,650 workers across the globe.

Cognyte Software's mailing address is 5420 FELTL ROAD, MINNETONKA MN, 55343. The official website for the company is www.cogentixmedical.com. The medical device company can be reached via phone at 972-9962-2300 or via email at ir@cogentixmedical.com.